» Articles » PMID: 10931529

Galectin-3 is Upregulated in Microglial Cells in Response to Ischemic Brain Lesions, but Not to Facial Nerve Axotomy

Overview
Journal J Neurosci Res
Specialty Neurology
Date 2000 Aug 10
PMID 10931529
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

We have recently demonstrated that the beta-galactoside-specific lectin galectin-3 is expressed by microglial cells in vitro, but not by normal resting microglia in vivo. In the present study, we have analyzed the expression of galectin-3 by microglia under traumatic conditions in vivo using two experimental rat models which substantially differ in the severity of lesion related to a breakdown of the blood-brain barrier (BBB) and the occurrence of inflammatory processes. These two features are absent after peripheral nerve lesion and present after cerebral ischemia. Here we show that, following facial nerve axotomy under conditions allowing (nerve anastomosis) or not subsequent regeneration (nerve resection), galectin-3 is not expressed by microglia in the corresponding facial nucleus 1-112 days after lesion. Galectin-3 is also absent in microglia at sites of a defective BBB in the normal brain, such as the circumventricular organs. Following experimental ischemia (i.e., permanent occlusion of the middle cerebral artery), in contrast, galectin-3 becomes strongly expressed by activated microglia as early as 48 hours after trauma, as determined by immunohistochemistry and Western blot analysis. Our findings suggest that the expression of galectin-3 by microglia in vivo correlates with the state of microglial activation.

Citing Articles

Nano-Plumber Reshapes Glymphatic-Lymphatic System to Sustain Microenvironment Homeostasis and Improve Long-Term Prognosis after Traumatic Brain Injury.

Tong S, Xie L, Xie X, Xu J, You Y, Sun Y Adv Sci (Weinh). 2023; 10(34):e2304284.

PMID: 37867233 PMC: 10700187. DOI: 10.1002/advs.202304284.


Fornix degeneration in risk factors of Alzheimer's disease, possible trigger of cognitive decline.

Lacalle-Aurioles M, Iturria-Medina Y Cereb Circ Cogn Behav. 2023; 4:100158.

PMID: 36703699 PMC: 9871745. DOI: 10.1016/j.cccb.2023.100158.


Nucleic acid drug vectors for diagnosis and treatment of brain diseases.

Lu Z, Shen J, Yang J, Wang J, Zhao R, Zhang T Signal Transduct Target Ther. 2023; 8(1):39.

PMID: 36650130 PMC: 9844208. DOI: 10.1038/s41392-022-01298-z.


Galectins-Potential Therapeutic Targets for Neurodegenerative Disorders.

Chaudhary S, Chaudhary S, Rawat S, Kulkarni A, Bilgrami A, Perveen A Int J Mol Sci. 2022; 23(19).

PMID: 36232314 PMC: 9569834. DOI: 10.3390/ijms231911012.


Novel Galectin-3 Roles in Neurogenesis, Inflammation and Neurological Diseases.

Soares L, Al-Dalahmah O, Hillis J, Young C, Asbed I, Sakaguchi M Cells. 2021; 10(11).

PMID: 34831271 PMC: 8618878. DOI: 10.3390/cells10113047.